纳米氧化铁
药物输送
医学
食品药品监督管理局
氧化铁纳米粒子
磁共振成像
纳米技术
药理学
纳米颗粒
材料科学
放射科
作者
Yue Huang,Jessica C. Hsu,Hyun Koo,David P. Cormode
出处
期刊:Theranostics
[Ivyspring International Publisher]
日期:2022-01-01
卷期号:12 (2): 796-816
被引量:89
摘要
Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities.
科研通智能强力驱动
Strongly Powered by AbleSci AI